401P Vibostolimab coformulated with pembrolizumab (vibo/pembro) + chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study

作者：C-H. Hsu, R. Dziadziuszko, D.A. Gomez Abreo, Sercan Aksoy, Marta Gil-Martín, Christoph Roderburg, Chung-Yang Yen, A. Arican, P. Cassier, S-A. Im, S-B. Kim, T Kudo, Sebastian Ochsenreither, Mehmet Alı Nahıt Şendur, K. Yonemori, C.I. Rojas, Qiaofei Liu, T. Keenan, Jane Healy, Mariusz Kwiatkowski · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.05.316 · 被引用次数：3 · 研究领域：Esophageal Cancer Research and Treatment、Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations